Search

Your search keyword '"Selva, Kevin J."' showing total 33 results
Start Over Author "Selva, Kevin J."
33 results on '"Selva, Kevin J."'

2. Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine

Author

Lee, Wen Shi, Audsley, Jennifer, Trieu, Mai-Chi, Reynaldi, Arnold, Aurelia, L. Carissa, Mehta, Palak H., Patterson, Joanne, Kent, Helen E., Nguyen, Julie, Amarasena, Thakshila, Esterbauer, Robyn, Haycroft, Ebene R., Ramanathan, Pradhipa, Davenport, Miles P., Schlub, Timothy E., Sasadeusz, Joseph, Wheatley, Adam K., Chung, Amy W., Juno, Jennifer A., Selva, Kevin J., and Kent, Stephen J.

Subjects
Testing, Physiological aspects, Health aspects, COVID-19 vaccines -- Physiological aspects -- Testing, Secondary immunization -- Physiological aspects -- Testing, Pharmacological research, Messenger RNA -- Health aspects, Pharmacology, Experimental
Abstract

Introduction Ancestral spike-based COVID-19 vaccines have reduced effectiveness in preventing symptomatic Omicron variant infections due to progressive neutralizing antibody escape (1). As such, COVID-19 vaccines have been serially updated to [...], BACKGROUND. There is uncertainty about the timing of booster vaccination against COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19. Studies focused on primary vaccination have previously suggested improved immunity with a longer interval between the first and second vaccine doses. METHODS. We conducted a randomized, controlled trial (November 2022-August 2023) and assigned 52 fully vaccinated adults to an immediate or a 3-month delayed bivalent Spikevax mRNA booster vaccine. Follow-up visits were completed for 48 participants (n = 24 per arm), with collection of saliva and plasma samples following each visit. RESULTS. The rise in neutralizing antibody responses to ancestral and Omicron strains were almost identical between the immediate and delayed vaccination arms. Analyses of plasma and salivary antibody responses (IgG, IgA), plasma antibody-dependent phagocytic activity, and the decay kinetics of antibody responses were similar between the 2 arms. Symptomatic and asymptomatic SARS-CoV-2 infections occurred in 49% (21 of 49) participants over the median 11.5 months of follow-up and were also similar between the 2 arms. CONCLUSIONS. Our data suggest that there was no benefit in delaying COVID-19 mRNA booster vaccination in preimmune populations during the present endemic phase of COVID-19. TRIAL REGISTRATION. Australian New Zealand Clinical Trials Registry number 12622000411741 (https://anzctr.org.au/Trial/ Registration/TrialReview.aspx?ACTRN=12622000411741). FUNDING. National Health and Medical Research Council, Australia (program grant App1149990) and Medical Research Future Fund (App2005544).

Published
2024
Full Text
View/download PDF

3. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain

Author

Wheatley, Adam K., Pymm, Phillip, Esterbauer, Robyn, Dietrich, Melanie H., Lee, Wen Shi, Drew, Damien, Kelly, Hannah G., Chan, Li-Jin, Mordant, Francesca L., Black, Katrina A., Adair, Amy, Tan, Hyon-Xhi, Juno, Jennifer A., Wragg, Kathleen M., Amarasena, Thakshila, Lopez, Ester, Selva, Kevin J., Haycroft, Ebene R., Cooney, James P., Venugopal, Hariprasad, Tan, Li Lynn, O Neill, Matthew T., Allison, Cody C., Cromer, Deborah, Davenport, Miles P., Bowen, Richard A., Chung, Amy W., Pellegrini, Marc, Liddament, Mark T., Glukhova, Alisa, Subbarao, Kanta, Kent, Stephen J., and Tham, Wai-Hong

Published
2021
Full Text
View/download PDF

4. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Author

Chappell, Keith J, Mordant, Francesca L, Li, Zheyi, Wijesundara, Danushka K, Ellenberg, Paula, Lackenby, Julia A, Cheung, Stacey T M, Modhiran, Naphak, Avumegah, Michael S, Henderson, Christina L, Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H O, Marrero-Hernandez, Sara, Selva, Kevin J, Chung, Amy W, Tran, Mai H, Tapley, Peter, Barnes, James, Reading, Patrick C, Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D, Hogarth, P Mark, Kedzierska, Katherine, Purcell, Damian F J, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R, and Munro, Trent P

Published
2021
Full Text
View/download PDF

5. SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

Author

Zhang, Wuji, Chua, Brendon Y., Selva, Kevin J., Kedzierski, Lukasz, Ashhurst, Thomas M., Haycroft, Ebene R., Shoffner-Beck, Suzanne K., Hensen, Luca, Boyd, David F., James, Fiona, Mouhtouris, Effie, Kwong, Jason C., Chua, Kyra Y. L., Drewett, George, Copaescu, Ana, Dobson, Julie E., Rowntree, Louise C., Habel, Jennifer R., Allen, Lilith F., Koay, Hui-Fern, Neil, Jessica A., Gartner, Matthew J., Lee, Christina Y., Andersson, Patiyan, Khan, Sadid F., Blakeway, Luke, Wisniewski, Jessica, McMahon, James H., Vine, Erica E., Cunningham, Anthony L., Audsley, Jennifer, Thevarajan, Irani, Seemann, Torsten, Sherry, Norelle L., Amanat, Fatima, Krammer, Florian, Londrigan, Sarah L., Wakim, Linda M., King, Nicholas J. C., Godfrey, Dale I., Mackay, Laura K., Thomas, Paul G., Nicholson, Suellen, Arnold, Kelly B., Chung, Amy W., Holmes, Natasha E., Smibert, Olivia C., Trubiano, Jason A., Gordon, Claire L., Nguyen, Thi H. O., and Kedzierska, Katherine

Published
2022
Full Text
View/download PDF

7. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Author

Wheatley, Adam K., Juno, Jennifer A., Wang, Jing J., Selva, Kevin J., Reynaldi, Arnold, Tan, Hyon-Xhi, Lee, Wen Shi, Wragg, Kathleen M., Kelly, Hannah G., Esterbauer, Robyn, Davis, Samantha K., Kent, Helen E., Mordant, Francesca L., Schlub, Timothy E., Gordon, David L., Khoury, David S., Subbarao, Kanta, Cromer, Deborah, Gordon, Tom P., Chung, Amy W., Davenport, Miles P., and Kent, Stephen J.

Published
2021
Full Text
View/download PDF

8. Systems serology detects functionally distinct coronavirus antibody features in children and elderly

Author

Selva, Kevin J., van de Sandt, Carolien E., Lemke, Melissa M., Lee, Christina Y., Shoffner, Suzanne K., Chua, Brendon Y., Davis, Samantha K., Nguyen, Thi H. O., Rowntree, Louise C., Hensen, Luca, Koutsakos, Marios, Wong, Chinn Yi, Mordant, Francesca, Jackson, David C., Flanagan, Katie L., Crowe, Jane, Tosif, Shidan, Neeland, Melanie R., Sutton, Philip, Licciardi, Paul V., Crawford, Nigel W., Cheng, Allen C., Doolan, Denise L., Amanat, Fatima, Krammer, Florian, Chappell, Keith, Modhiran, Naphak, Watterson, Daniel, Young, Paul, Lee, Wen Shi, Wines, Bruce D., Mark Hogarth, P., Esterbauer, Robyn, Kelly, Hannah G., Tan, Hyon-Xhi, Juno, Jennifer A., Wheatley, Adam K., Kent, Stephen J., Arnold, Kelly B., Kedzierska, Katherine, and Chung, Amy W.

Published
2021
Full Text
View/download PDF

9. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19

Author

Tosif, Shidan, Neeland, Melanie R., Sutton, Philip, Licciardi, Paul V., Sarkar, Sohinee, Selva, Kevin J., Do, Lien Anh Ha, Donato, Celeste, Quan Toh, Zheng, Higgins, Rachel, Van de Sandt, Carolien, Lemke, Melissa M., Lee, Christina Y., Shoffner, Suzanne K., Flanagan, Katie L., Arnold, Kelly B., Mordant, Francesca L., Mulholland, Kim, Bines, Julie, Dohle, Kate, Pellicci, Daniel G., Curtis, Nigel, McNab, Sarah, Steer, Andrew, Saffery, Richard, Subbarao, Kanta, Chung, Amy W., Kedzierska, Katherine, Burgner, David P., and Crawford, Nigel W.

Published
2020
Full Text
View/download PDF

10. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections

Author

Selva, Kevin J., primary, Ramanathan, Pradhipa, additional, Haycroft, Ebene R., additional, Reynaldi, Arnold, additional, Cromer, Deborah, additional, Tan, Chee Wah, additional, Wang, Lin-Fa, additional, Wines, Bruce D., additional, Hogarth, P. Mark, additional, Downie, Laura E., additional, Davis, Samantha K., additional, Purcell, Ruth A., additional, Kent, Helen E., additional, Juno, Jennifer A., additional, Wheatley, Adam K., additional, Davenport, Miles P., additional, Kent, Stephen J., additional, and Chung, Amy W., additional

Published
2023
Full Text
View/download PDF

11. Mucosal antibody responses following Vaxzevria vaccination

Author

Selva, Kevin J, primary, Ramanathan, Pradhipa, additional, Haycroft, Ebene R, additional, Tan, Chee Wah, additional, Wang, Lin‐Fa, additional, Downie, Laura E, additional, Davis, Samantha K, additional, Purcell, Ruth A, additional, Kent, Helen E, additional, Juno, Jennifer A, additional, Wheatley, Adam K, additional, Davenport, Miles P, additional, Kent, Stephen J, additional, and Chung, Amy W, additional

Published
2023
Full Text
View/download PDF

13. Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbations

Author

Habel, Jennifer R., primary, Chua, Brendon Y., additional, Kedzierski, Lukasz, additional, Selva, Kevin J., additional, Damelang, Timon, additional, Haycroft, Ebene R., additional, Nguyen, Thi H.O., additional, Koay, Hui-Fern, additional, Nicholson, Suellen, additional, McQuilten, Hayley A., additional, Jia, Xiaoxiao, additional, Allen, Lilith F., additional, Hensen, Luca, additional, Zhang, Wuji, additional, van de Sandt, Carolien E., additional, Neil, Jessica A., additional, Pragastis, Katherine, additional, Lau, Jillian S.Y., additional, Jumarang, Jaycee, additional, Allen, E. Kaitlynn, additional, Amanant, Fatima, additional, Krammer, Florian, additional, Wragg, Kathleen M., additional, Juno, Jennifer A., additional, Wheatley, Adam K., additional, Tan, Hyon-Xhi, additional, Pell, Gabrielle, additional, Walker, Susan, additional, Audsley, Jennifer, additional, Reynaldi, Arnold, additional, Thevarajan, Irani, additional, Denholm, Justin T., additional, Subbarao, Kanta, additional, Davenport, Miles P., additional, Hogarth, P. Mark, additional, Godfrey, Dale I., additional, Cheng, Allen C., additional, Tong, Steven Y.C., additional, Bond, Katherine, additional, Williamson, Deborah A., additional, McMahon, James H., additional, Thomas, Paul G., additional, Pannaraj, Pia S., additional, James, Fiona, additional, Holmes, Natasha E., additional, Smibert, Olivia C., additional, Trubiano, Jason A., additional, Gordon, Claire L., additional, Chung, Amy W., additional, Whitehead, Clare L., additional, Kent, Stephen J., additional, Lappas, Martha, additional, Rowntree, Louise C., additional, and Kedzierska, Katherine, additional

Published
2023
Full Text
View/download PDF

14. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques

Author

Chua, Brendon Y., primary, Sekiya, Toshiki, additional, Koutsakos, Marios, additional, Nomura, Naoki, additional, Rowntree, Louise C., additional, Nguyen, Thi H. O., additional, McQuilten, Hayley A., additional, Ohno, Marumi, additional, Ohara, Yuki, additional, Nishimura, Tomohiro, additional, Endo, Masafumi, additional, Itoh, Yasushi, additional, Habel, Jennifer R., additional, Selva, Kevin J., additional, Wheatley, Adam K., additional, Wines, Bruce D., additional, Hogarth, P. Mark, additional, Kent, Stephen J., additional, Chung, Amy W., additional, Jackson, David C., additional, Brown, Lorena E., additional, Shingai, Masashi, additional, Kedzierska, Katherine, additional, and Kida, Hiroshi, additional

Published
2022
Full Text
View/download PDF

15. Virology and immune dynamics reveal high household transmission of ancestral SARS‐CoV‐2 strain

Author

Tosif, Shidan, primary, Haycroft, Ebene R., additional, Sarkar, Sohinee, additional, Toh, Zheng Quan, additional, Do, Lien Anh Ha, additional, Donato, Celeste M., additional, Selva, Kevin J., additional, Hoq, Monsurul, additional, Overmars, Isabella, additional, Nguyen, Jill, additional, Lee, Lai‐Yang, additional, Clifford, Vanessa, additional, Daley, Andrew, additional, Mordant, Francesa L., additional, McVernon, Jodie, additional, Mulholland, Kim, additional, Marcato, Adrian J., additional, Smith, Miranda Z., additional, Curtis, Nigel, additional, McNab, Sarah, additional, Saffery, Richard, additional, Kedzierska, Katherine, additional, Subarrao, Kanta, additional, Burgner, David, additional, Steer, Andrew, additional, Bines, Julie E., additional, Sutton, Philip, additional, Licciardi, Paul V., additional, Chung, Amy W., additional, Neeland, Melanie R., additional, and Crawford, Nigel W., additional

Published
2022
Full Text
View/download PDF

16. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques

Author

Chua, Brendon Y., Sekiya, Toshiki, Koutsakos, Marios, Nomura, Naoki, Rowntree, Louise C., Nguyen, Thi H. O., McQuilten, Hayley A., 1000050794202, Ohno, Marumi, Ohara, Yuki, Nishimura, Tomohiro, Endo, Masafumi, Itoh, Yasushi, Habel, Jennifer R., Selva, Kevin J., Wheatley, Adam K., Wines, Bruce D., Hogarth, P. Mark, Kent, Stephen J., Chung, Amy W., Jackson, David C., Brown, Lorena E., 1000080421981, Shingai, Masashi, Kedzierska, Katherine, 1000010109506, Kida, Hiroshi, Chua, Brendon Y., Sekiya, Toshiki, Koutsakos, Marios, Nomura, Naoki, Rowntree, Louise C., Nguyen, Thi H. O., McQuilten, Hayley A., 1000050794202, Ohno, Marumi, Ohara, Yuki, Nishimura, Tomohiro, Endo, Masafumi, Itoh, Yasushi, Habel, Jennifer R., Selva, Kevin J., Wheatley, Adam K., Wines, Bruce D., Hogarth, P. Mark, Kent, Stephen J., Chung, Amy W., Jackson, David C., Brown, Lorena E., 1000080421981, Shingai, Masashi, Kedzierska, Katherine, 1000010109506, and Kida, Hiroshi

Abstract

Although antibody-inducing split virus vaccines (SV) are currently the most effective way to combat seasonal influenza, their efficacy can be modest, especially in immunologically-naive individuals. We investigated immune responses towards inactivated whole influenza virus particle vaccine (WPV) formulations, predicated to be more immunogenic, in a non-human primate model, as an important step towards clinical testing in humans. Comprehensive analyses were used to capture 46 immune parameters to profile how WPV-induced responses differed to those elicited by antigenically-similar SV formulations. Naive cynomolgus macaques vaccinated with either monovalent or quadrivalent WPV consistently induced stronger antibody responses and hemagglutination inhibition (HI) antibody titres against vaccine-matched viruses compared to SV formulations, while acute reactogenic effects were similar. Responses in WPV-primed animals were further increased by boosting with the same formulation, conversely to modest responses after priming and boosting with SV. 28-parameter multiplex bead array defined key antibody features and showed that while both WPV and SV induced elevated IgG responses against A/H1N1 nucleoprotein, only WPV increased IgG responses against A/H1N1 hemagglutinin (HA) and HA-Stem, and higher IgA responses to A/H1N1-HA after each vaccine dose. Antibodies to A/H1N1-HA and HA-Stem that could engage Fc gamma R2a and Fc gamma R3a were also present at higher levels after one dose of WPV compared to SV and remained elevated after the second dose. Furthermore, WPV-enhanced antibody responses were associated with higher frequencies of HA-specific B-cells and IFN-gamma-producing CD4(+) T-cell responses. Our data additionally demonstrate stronger boosting of HI titres by WPV following prior infection and support WPV administered as a priming dose irrespective of the follow up vaccine for the second dose. Our findings thus show that compared to SV vaccination, WPV-induced humoral re

Published
2022

17. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine

Author

Ju, Yi, primary, Lee, Wen Shi, additional, Pilkington, Emily H., additional, Kelly, Hannah G., additional, Li, Shiyao, additional, Selva, Kevin J., additional, Wragg, Kathleen M., additional, Subbarao, Kanta, additional, Nguyen, Thi H. O., additional, Rowntree, Louise C., additional, Allen, Lilith F., additional, Bond, Katherine, additional, Williamson, Deborah A., additional, Truong, Nghia P., additional, Plebanski, Magdalena, additional, Kedzierska, Katherine, additional, Mahanty, Siddhartha, additional, Chung, Amy W., additional, Caruso, Frank, additional, Wheatley, Adam K., additional, Juno, Jennifer A., additional, and Kent, Stephen J., additional

Published
2022
Full Text
View/download PDF

18. Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation

Author

Habel, Jennifer R, primary, Chua, Brendon Y, additional, Kedzierski, Lukasz, additional, Selva, Kevin J, additional, Damelang, Timon, additional, Haycroft, Ebene R, additional, Nguyen, Thi HO, additional, Koay, Hui-Fern, additional, Nicholson, Suellen, additional, McQuilten, Hayley, additional, Jia, Xiaoxiao, additional, Allen, Lilith F, additional, Hensen, Luca, additional, Zhang, Wuji, additional, van de Sandt, Carolien E, additional, Neil, Jessica A, additional, Amanant, Fatima, additional, Krammer, Florian, additional, Wragg, Kathleen, additional, Juno, Jennifer A, additional, Wheatley, Adam K, additional, Tan, Hyon-Xhi, additional, Pell, Gabrielle, additional, Audsley, Jennifer, additional, Reynaldi, Arnold, additional, Thevarajan, Irani, additional, Denholm, Justin, additional, Subbarao, Kanta, additional, Davenport, Miles P, additional, Hogarth, Mark, additional, Godrey, Dale I, additional, Cheng, Allen C, additional, Tong, Steven YC, additional, Bond, Katherine, additional, Williamson, Deborah A, additional, James, Fiona, additional, Holmes, Natasha E, additional, Smibert, Olivia C, additional, Trubiano, Jason A, additional, Gordon, Claire L, additional, Chung, Amy W, additional, Whitehead, Claire, additional, Kent, Stephen J, additional, Lappas, Martha, additional, Rowntree, Louise C, additional, and Kedzierska, Katherine, additional

Published
2022
Full Text
View/download PDF

20. Novel IgG3 Allotype Identified in Women From Malaria Endemic Regions That Modulates Fc Effector Functions

Author

Damelang, Timon, primary, Kassa, Meseret W., additional, Lopez, Ester, additional, Selva, Kevin J., additional, Davis, Samantha K., additional, Aitken, Elizabeth H., additional, Hasang, Wina, additional, Lufele, Elvin, additional, Warta, Putri, additional, Esterbauer, Robyn, additional, Amarasena, Thakshila, additional, Killian, Martin, additional, Jally, Shadrach, additional, Tavul, Livingstone, additional, Ome-Kaius, Maria, additional, del Pilar Quintana, Maria, additional, Hviid, Lars, additional, Wheatley, Adam K., additional, Wines, Bruce D., additional, Hogarth, P. Mark, additional, Unger, Holger W., additional, Kent, Stephen J., additional, Rogerson, Stephen J., additional, and Chung, Amy, additional

Published
2022
Full Text
View/download PDF

21. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

Author

Lopez, Ester, primary, Haycroft, Ebene R., additional, Adair, Amy, additional, Mordant, Francesca L., additional, O’Neill, Matthew T., additional, Pymm, Phillip, additional, Redmond, Samuel J., additional, Lee, Wen Shi, additional, Gherardin, Nicholas A., additional, Wheatley, Adam K., additional, Juno, Jennifer A., additional, Selva, Kevin J., additional, Davis, Samantha K., additional, Grimley, Samantha L., additional, Harty, Leigh, additional, Purcell, Damian F.J., additional, Subbarao, Kanta, additional, Godfrey, Dale I., additional, Kent, Stephen J., additional, Tham, Wai-Hong, additional, and Chung, Amy W., additional

Published
2021
Full Text
View/download PDF

22. Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation

Author

Habel, Jennifer R, primary, Chua, Brendon Y, additional, Kedzierski, Lukasz, additional, Selva, Kevin J, additional, Damelang, Timon, additional, Haycroft, Ebene R, additional, Nguyen, Thi HO, additional, Koay, Hui-Fern, additional, Nicholson, Suellen, additional, McQuilten, Hayley, additional, Jia, Xiaoxiao, additional, Allen, Lilith F, additional, Hensen, Luca, additional, Zhang, Wuji, additional, van de Sandt, Carolien E, additional, Neil, Jessica A, additional, Amanat, Fatima, additional, Krammer, Florian, additional, Wragg, Kathleen, additional, Juno, Jennifer A, additional, Wheatley, Adam K, additional, Tan, Hyon-Xhi, additional, Pell, Gabrielle, additional, Audsley, Jennifer, additional, Thevarajan, Irani, additional, Denholm, Justin, additional, Subbarao, Kanta, additional, Godfrey, Dale I, additional, Cheng, Allen C, additional, Tong, Steven YC, additional, Bond, Katherine, additional, Williamson, Deborah A, additional, James, Fiona, additional, Holmes, Natasha E, additional, Smibert, Olivia C, additional, Trubiano, Jason A, additional, Gordon, Claire L, additional, Chung, Amy W, additional, Whitehead, Clare L, additional, Kent, Stephen J, additional, Lappas, Martha, additional, Rowntree, Louise C, additional, and Kedzierska, Katherine, additional

Published
2021
Full Text
View/download PDF

23. Tear antibodies to SARS-CoV-2: implications for transmission

Author

Selva, Kevin J., primary, Davis, Samantha K., additional, Haycroft, Ebene R., additional, Lee, Wen Shi, additional, Lopez, Ester, additional, Reynaldi, Arnold, additional, Davenport, Miles P., additional, Kent, Helen E., additional, Juno, Jennifer A., additional, Chung, Amy W., additional, and Kent, Stephen J., additional

Published
2021
Full Text
View/download PDF

24. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay

Author

Lopez, Ester, primary, Haycroft, Ebene R., additional, Adair, Amy, additional, Mordant, Francesca L., additional, O’Neill, Matthew T., additional, Pymm, Phillip, additional, Redmond, Samuel, additional, Gherardin, Nicholas A., additional, Wheatley, Adam K., additional, Juno, Jennifer. A., additional, Selva, Kevin J., additional, Davis, Samantha, additional, Harty, Leigh, additional, Purcell, Damian F.J., additional, Subbarao, Kanta, additional, Godfrey, Dale I., additional, Kent, Stephen J., additional, Tham, Wai-Hong, additional, and Chung, Amy W., additional

Published
2021
Full Text
View/download PDF

25. First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2

Author

Chappell, Keith Joseph, primary, Mordant, Francesca L., additional, Li, Zheyi, additional, Wijesundara, Danushka K., additional, Ellenberg, Paula, additional, Lackenby, Julia, additional, Cheung, Stacey, additional, Modhiran, Naphak, additional, Avumegah, Michael S., additional, Henderson, Christina L., additional, Hoger, Kym, additional, Bennet, Jillian, additional, Hensen, Luca, additional, Nguyen, Thi H. O., additional, Marrero-Hernandez, Sara, additional, Selva, Kevin J., additional, AW, Chung, additional, Tran, Mai H., additional, Tapley, Peter, additional, Reading, Patrick, additional, Nicholson, Suellen, additional, Corby, Stavroula, additional, Holgate, Thomas, additional, Wines, Bruce D., additional, Hogarth, P. Mark, additional, Kedzierska, Katherine, additional, Purcell, Damian, additional, Ranasinghe, Charani, additional, Subbarao, Kanta, additional, Watterson, Daniel, additional, Young, Paul, additional, and Munro, Trent P., additional

Published
2021
Full Text
View/download PDF

26. Tear antibodies to SARS‐CoV‐2: implications for transmission

Author

Selva, Kevin J, primary, Davis, Samantha K, additional, Haycroft, Ebene R, additional, Lee, Wen Shi, additional, Lopez, Ester, additional, Reynaldi, Arnold, additional, Davenport, Miles P, additional, Kent, Helen E, additional, Juno, Jennifer A, additional, Chung, Amy W, additional, and Kent, Stephen J, additional

Published
2021
Full Text
View/download PDF

27. Evolution of immunity to SARS-CoV-2

Author

Wheatley, Adam K., primary, Juno, Jennifer A., additional, Wang, Jing J., additional, Selva, Kevin J., additional, Reynaldi, Arnold, additional, Tan, Hyon-Xhi, additional, Shi Lee, Wen, additional, Wragg, Kathleen M., additional, Kelly, Hannah G., additional, Esterbauer, Robyn, additional, Davis, Samantha K., additional, Kent, Helen E., additional, Mordant, Francesca L., additional, Schlub, Timothy E., additional, Gordon, David L., additional, Khoury, David S., additional, Subbarao, Kanta, additional, Cromer, Deborah, additional, Gordon, Tom P., additional, Chung, Amy W., additional, Davenport, Miles P., additional, and Kent, Stephen J., additional

Published
2020
Full Text
View/download PDF

28. Distinct systems serology features in children, elderly and COVID patients

Author

Selva, Kevin J., primary, van de Sandt, Carolien E., additional, Lemke, Melissa M., additional, Lee, Christina Y., additional, Shoffner, Suzanne K., additional, Chua, Brendon Y., additional, Nguyen, Thi H.O., additional, Rowntree, Louise C., additional, Hensen, Luca, additional, Koutsakos, Marios, additional, Wong, Chinn Yi, additional, Jackson, David C., additional, Flanagan, Katie L., additional, Crowe, Jane, additional, Cheng, Allen C., additional, Doolan, Denise L., additional, Amanat, Fatima, additional, Krammer, Florian, additional, Chappell, Keith, additional, Modhiran, Naphak, additional, Watterson, Daniel, additional, Young, Paul, additional, Wines, Bruce, additional, Hogarth, P. Mark, additional, Esterbauer, Robyn, additional, Kelly, Hannah G., additional, Tan, Hyon-Xhi, additional, Juno, Jennifer A., additional, Wheatley, Adam K., additional, Kent, Stephen J., additional, Arnold, Kelly B., additional, Kedzierska, Katherine, additional, and Chung, Amy W., additional

Published
2020
Full Text
View/download PDF

32. Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models

Author

Juno, Jennifer A., primary, Wragg, Kathleen M., additional, Kristensen, Anne B., additional, Lee, Wen Shi, additional, Selva, Kevin J., additional, van der Sluis, Renee M., additional, Kelleher, Anthony D., additional, Bavinton, Benjamin R., additional, Grulich, Andrew E., additional, Lewin, Sharon R., additional, Kent, Stephen J., additional, and Parsons, Matthew S., additional

Published
2019
Full Text
View/download PDF

33. Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines.

Author

Lee WS, Selva KJ, Audsley J, Kent HE, Reynaldi A, Schlub TE, Cromer D, Khoury DS, Peck H, Aban M, Vu MN, Zheng MZ, Chung AW, Koutsakos M, Tan HX, Wheatley AK, Juno JA, Rockman S, Davenport MP, Barr I, and Kent SJ

Subjects
Humans, Female, Male, Adult, Middle Aged, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, Aged, Immunogenicity, Vaccine, Hemagglutination Inhibition Tests, Vaccines, Synthetic immunology, Vaccines, Synthetic administration & dosage, Young Adult, Vaccination methods, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Influenza Vaccines immunology, Influenza Vaccines administration & dosage, SARS-CoV-2 immunology, COVID-19 prevention & control, COVID-19 immunology, Antibodies, Viral immunology, Antibodies, Viral blood, Vaccines, Inactivated immunology, Vaccines, Inactivated administration & dosage, Influenza, Human prevention & control, Influenza, Human immunology, mRNA Vaccines immunology
Abstract

BACKGROUNDThe immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are more immunogenic if given in the same arm or opposite arms. Murine studies suggest mRNA vaccines can adjuvant influenza vaccines when coformulated and codelivered.METHODSWe randomly assigned 56 adults to receive the Afluria quadrivalent inactivated influenza and Moderna monovalent SARS-CoV-2 XBB.1.5 mRNA vaccines, either in opposite arms or both in the same arm at the same site. The primary endpoint was the difference in median combined serum hemagglutination inhibition titer to the H1, H3, and B-Vic vaccine influenza strains after vaccination.RESULTSWe found no significant difference in hemagglutination inhibition antibody levels between the groups (P = 0.30), with the same-arm group having a 1.26-fold higher titer than the opposite-arm group. There were no differences in analyses of antibodies against individual influenza strains or in nasal or saliva antibody levels. While both binding and neutralizing antibody titers against SARS-CoV-2 were not significantly different between groups postvaccination, there was a higher fold-change in BA.5 and ancestral strain neutralizing antibodies in the opposite-arm group.CONCLUSIONInfluenza vaccination is equivalently immunogenic if given in the same arm or opposite arms as the SARS-CoV-2 vaccine, but it may be preferable to administer the SARS-CoV-2 vaccine at a different site from influenza vaccines.TRIAL REGISTRATIONAustralian New Zealand Clinical Trials Registry ACTRN12624000445572.FUNDINGAustralian National Health and Medical Research Council, Australian Medical Research Future Fund, and National Institutes of Health (UH2AI176172).

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results